SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)

Trial Profile

SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Brincidofovir (Primary) ; Valganciclovir
  • Indications Cytomegalovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms BCV CMV vGCV; SURPASS
  • Sponsors Chimerix
  • Most Recent Events

    • 20 Feb 2016 According to a Chimerix media release, status changed from active, no longer recruiting to discontinued.
    • 20 Feb 2016 According to a Chimerix media release, the company has elected to close the Phase 3 SUSTAIN and SURPASS trials based on review of data from SUPPRESS trial.
    • 11 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top